News Author: Mark L. Fuerst Publish date: December 23, 2016
Photo by Bill Branson
SAN DIEGO—Trial results suggest treatment with the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 is feasible for mos...
News Author: Mark L. Fuerst Publish date: December 22, 2016
SAN DIEGO—Substituting obinutuzumab for rituximab in combination with CHOP chemotherapy does not improve outcomes in patients with previously untreate...
News Author: Mark L. Fuerst Publish date: December 7, 2016
© Todd Buchanan 2016
SAN DIEGO—Updated results of the EURO-SKI trial support the idea that certain chronic myeloid leukemia (CML) patients can safe...
News Author: Mark L. Fuerst Publish date: December 7, 2016
2016 ASH Annual Meeting
SAN DIEGO—Many patients living with myeloproliferative neoplasms (MPNs) have a high burden of disease that affects their qu...
News Author: Mark L. Fuerst Publish date: December 6, 2016
© Todd Buchanan 2016
SAN DIEGO—A targeted therapy combined with standard chemotherapy can produce rapid, deep remissions in patients with newly dia...
News Author: Mark L. Fuerst Publish date: June 17, 2016
the ASCO Annual Meeting
© ASCO/Todd Buchanan
CHICAGO—Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT)...
News Author: Mark L. Fuerst Publish date: June 17, 2016
© ASCO/Brian Powers
CHICAGO—Treatment dose and schedule, as well as a patient’s tumor burden, influence the outcome of therapy with chimeric antige...
News Author: Mark L. Fuerst Publish date: June 13, 2016
CHICAGO—Nearly 60% of chronic myeloid leukemia (CML) patients who switch to nilotinib from imatinib maintain treatment-free remission for 48 wee...
News Author: Mark L. Fuerst Publish date: December 30, 2015
Photo courtesy of the
University of Navarra
ORLANDO, FL—The addition of panobinostat to bortezomib-dexamethasone therapy in relapsed or refractory...
News Author: Mark L. Fuerst Publish date: December 17, 2015
Photo courtesy of Penn Medicine
ORLANDO, FL—CTL019, a CD19 chimeric antigen receptor (CAR) T-cell therapy, can persist for 3 years or longer in chi...
News Author: Mark L. Fuerst Publish date: December 16, 2015
ASH Annual Meeting
Photo courtesy of ASH
ORLANDO, FL—Five-year results from the COMFORT-II trial appear to confirm that treatment with ruxolitinib...
News Author: Mark L. Fuerst Publish date: June 13, 2015
©ASCO/Rodney White
CHICAGO—Combination regimens including the histone deacetylase inhibitor panobinostat can produce durable responses and prolong ...
News Author: Mark L. Fuerst Publish date: June 11, 2015
©ASCO/Rodney White CHICAGO—The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin lymph...
News Author: Mark L. Fuerst Publish date: December 16, 2014
Photo courtesy of ASH
SAN FRANCISCO—Iron chelation therapy significantly improves survival for patients with lower-risk myelodysplastic syndrome (M...
News Author: Mark L. Fuerst Publish date: December 13, 2014
the 2014 ASH Annual Meeting
SAN FRANCISCO—A recombinant factor VIII (FVIII) Fc fusion protein is effective for routine prophylaxis and control of b...
